Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
J Comp Eff Res
; 12(5): e220098, 2023 05.
Article
en En
| MEDLINE
| ID: mdl-37079341
ABSTRACT
Aim:
Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments.Methods:
An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral and intravenous [IV] topotecan, and platinum re-challenge) identified by systematic literature review. Network meta-analysis methods estimated relative treatment effects.Results:
In platinum-sensitive patients, lurbinectedin demonstrated a survival benefit and favorable safety profile versus oral and IV topotecan and platinum re-challenge (overall survival, hazard ratio [HR] 0.43; 95% credible interval [CrI] 0.27, 0.67; HR 0.43; 95% CrI 0.26, 0.70; HR 0.42; 95% CrI 0.30, 0.58 respectively).Conclusion:
Lurbinectedin showed a robust survival benefit and favorable safety versus other SCLC treatments in 2L platinum-sensitive SCLC.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma Pulmonar de Células Pequeñas
/
Neoplasias Pulmonares
Tipo de estudio:
Clinical_trials
/
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
J Comp Eff Res
Año:
2023
Tipo del documento:
Article
País de afiliación:
Reino Unido